BIOCRYST PHARMACEUTICALS INC

BioCryst Pharmaceuticals reported a net income of $78.4 million for Q2 2026, a significant increase from $5.1 million in Q2 2025. However, for the first six months of 2026, the company posted a net loss of $643.4 million, primarily due to a $697.8 million acquired in-process research and development expense related to the Astria Therapeutics acquisition. Total revenues for Q2 rose 33.6% to $218.3 million, and for H1 increased 21.3% to $374.7 million. The company also secured a new $400 million term loan.

BioCryst Pharmaceuticals reported strong second-quarter 2026 financial results, with total net revenue increasing 34% year-over-year to $218.3 million and ORLADEYO net revenue reaching $158.2 million. The company achieved a GAAP operating profit of $98.5 million and a Non-GAAP operating profit of $113.2 million. BioCryst raised its full-year 2026 total revenue guidance to $690 million to $715 million and improved its non-GAAP operating expense outlook. Key corporate developments include the launch of ORLADEYO oral pellets for pediatric patients and the completion of enrollment in the pivotal navenibart study.

BioCryst Pharmaceuticals announced its plan to discontinue internal discovery programs and close its Discovery Center of Excellence facility in Birmingham, Alabama, as part of a strategic evolution. The company estimates one-time expenses of $6.2 million to $7.5 million for employee termination benefits and severance, with $5.3 million to $6.6 million expected as cash expenditures. Management's analysis of additional costs related to the facility closure, such as contract and lease termination or asset impairment, is still ongoing, and an estimate for these costs is not yet available.

BioCryst Pharmaceuticals, Inc. announced that it will report its second quarter 2026 financial results on Wednesday, August 5, 2026. Following the release, BioCryst management will host a conference call and webcast at 8:30 a.m. ET to discuss the results and provide a corporate update. The webcast and replay will be accessible on the company's investor relations website.

BioCryst Pharmaceuticals announced the appointment of David W. Jenkins, MA, PhD, as its new Chief Scientific Officer, effective immediately. Dr. Jenkins will lead a research team focused on leveraging external innovation, capabilities, and partnerships to accelerate the delivery of rare disease therapies. This appointment reinforces BioCryst's strategic pivot in R&D towards high-impact external opportunities and building a high-value pipeline.

BioCryst Pharmaceuticals announced that its compensation committee granted equity awards to nine newly-hired employees. These awards include stock options to purchase an aggregate of 33,950 shares and restricted stock units (RSUs) covering an aggregate of 91,750 shares of BioCryst common stock. The grants, made on July 1, 2026, serve as material inducements for their employment and will vest in four equal annual installments.

BioCryst Pharmaceuticals announced a strategic restructuring plan to discontinue its internal discovery programs and close its Birmingham, Alabama facility by the end of 2026. This move is part of an evolution to strengthen its rare disease pipeline through external innovation, leading to a reduction in its 2026 non-GAAP operating expense guidance to $420-$440 million from $450-$470 million. The company also reaffirmed its 2026 revenue guidance and provided updates on its clinical pipeline, including the completion of navenibart's Phase 3 enrollment and resolution of an ORLADEYO manufacturing delay.

BioCryst Pharmaceuticals announced a strategic shift to prioritize external innovation, discontinuing internal discovery programs and closing its Birmingham Discovery Center by the end of 2026. This restructuring is expected to improve efficiency and lower costs, leading to an updated 2026 non-GAAP operating expense guidance of $420-$440 million, down from $450-$470 million. The company reaffirmed its 2026 revenue guidance and provided positive updates on its clinical pipeline, including completed enrollment for navenibart's Phase 3 study and resolved manufacturing delays for ORLADEYO oral pellets.

BioCryst Pharmaceuticals, Inc. held its 2026 Annual Meeting of Stockholders, where several key proposals were approved. Stockholders voted to amend and restate the Stock Incentive Plan, increasing the number of shares available for issuance by 7,000,000. Additionally, three directors were elected, the appointment of Ernst & Young LLP as independent accountants for 2026 was ratified, and a non-binding advisory vote approved the company's executive compensation.

BioCryst Pharmaceuticals announced new clinical data and real-world evidence for ORLADEYO and new data from the Phase 1b/2 ALPHA-STAR study of investigational navenibart, both for hereditary angioedema (HAE). The data, to be presented at EAACI, reinforce the strength of BioCryst's HAE portfolio, showing consistent reductions in HAE attack burden and healthcare utilization across diverse patient populations for ORLADEYO, and consistent attack rate reductions for navenibart across patient subgroups, supporting its Phase 3 evaluation.